239 related articles for article (PubMed ID: 30194084)
1. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
Galanina N; Goodman AM; Cohen PR; Frampton GM; Kurzrock R
Cancer Immunol Res; 2018 Oct; 6(10):1129-1135. PubMed ID: 30194084
[TBL] [Abstract][Full Text] [Related]
2. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.
Spano JP; Veyri M; Gobert A; Guihot A; Perré P; Kerjouan M; Brosseau S; Cloarec N; Montaudié H; Helissey C; Flament T; Gounant V; Lavolé A; Poizot-Martin I; Katlama C
AIDS; 2019 Sep; 33(11):F13-F19. PubMed ID: 31259762
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
6. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
7. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
Uldrick TS; Wyvill KM; Kumar P; O'Mahony D; Bernstein W; Aleman K; Polizzotto MN; Steinberg SM; Pittaluga S; Marshall V; Whitby D; Little RF; Yarchoan R
J Clin Oncol; 2012 May; 30(13):1476-83. PubMed ID: 22430271
[TBL] [Abstract][Full Text] [Related]
9. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Zahavi DJ; Weiner LM
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Ostios-Garcia L; Faig J; Leonardi GC; Adeni AE; Subegdjo SJ; Lydon CA; Rangachari D; Huberman MS; Sehgal K; Shea M; VanderLaan PA; Cheng MP; Marty FM; Hammond SP; Costa DB; Awad MM
J Thorac Oncol; 2018 Jul; 13(7):1037-1042. PubMed ID: 29631035
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
12. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.
Daly ML; Fogo A; McDonald C; Morris-Jones R
Clin Exp Dermatol; 2014 Jan; 39(1):7-12. PubMed ID: 23691969
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
14. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study.
Saller J; Walko CM; Millis SZ; Henderson-Jackson E; Makanji R; Brohl AS
J Natl Compr Canc Netw; 2018 Jul; 16(7):797-800. PubMed ID: 30006421
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L; Jackie Wang CC; Joshi H; Lensing S; Lee J; Ramos JC; Baiocchi R; Ratner L; Rubinstein PG; Ambinder R; Henry D; Streicher H; Little RF; Chiao E; Dittmer DP; Einstein MH; Cesarman E; Mitsuyasu R; Sparano JA;
Cancer; 2024 Mar; 130(6):985-994. PubMed ID: 37962072
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
[TBL] [Abstract][Full Text] [Related]
17. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Tiu C; Wong A; Herschtal A; Mileshkin L
Asia Pac J Clin Oncol; 2018 Aug; 14(4):337-342. PubMed ID: 29498208
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
